Structure Therapeutics Inc. (GPCR)
- Sector
- Pharmaceuticals
- Last price
- $18.17
- As of
Kresmion compiles this page from GPCR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Structure Therapeutics Inc. (GPCR): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-09.
See the full GPCR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for GPCR on one page. Preview it with sample data, then open it live with a free account.
Preview the GPCR dossierActive events for GPCR
- mediumEarnings below estimates
Q3-2026: Missed consensus by 235.6%, EPS $-1.98 vs $-0.59 estimate
- mediumEarnings below estimates
Q2-2026: Missed consensus by 20.8%, EPS $-0.49 vs $-0.4056 estimate
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 52% of GPCR (2026Q1)
- high13F: large increase
D. E. Shaw & Co., Inc. added +2275% to GPCR (2026Q1)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +90% to GPCR (2026Q1)
FREE, NO ACCOUNT
Every event on GPCR, as it fires
You are seeing 5 of 8 events recorded on GPCR since 2026-05-30.
The five above landed across 3 days. The other 3 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, GPCR
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on GPCR
GPCR against its peers
GPCR's return on equity of -9.3% ranks in the 50th percentile of 22 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-03-31 and 2026-06-30.
| Metric | GPCR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 431M | n/a | 20 |
| Gross margin | n/a | 73.3% | n/a | 11 |
| Operating margin | n/a | 2.6% | n/a | 19 |
| Net margin | n/a | 0.3% | n/a | 20 |
| Return on equity | -9.3% | -11.5% | 50 | 22 |
| P / E | n/a | 14.7x | n/a | 9 |
| 1 year | -49.1% | 11.1% | 6 | 24 |
Peers (25): PAHC, PCRX, NUVB, OCUL, INVA, NKTR, ANIP, SUPN, AMPH, OMER, ANRO, TRVI, HRMY, ESPR.D, COLL, ALMS, XERS, BHC, ACRS, OGN, TARS, AMLX, LQDA, AVIR, ACB. Fiscal periods ending between 2025-03-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (GPCR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in GPCR on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on GPCR in the last 180 days.
Upstream: SEC EDGAR filings for GPCR
Kresmion, "Structure Therapeutics Inc. (GPCR) institutional holdings and SEC filings", data as of 2026-11-17, https://kresmion.com/research/GPCR. Upstream data: SEC EDGAR filings for GPCR.
Link to this data (HTML):
<a href="https://kresmion.com/research/GPCR">Structure Therapeutics Inc. (GPCR) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow GPCR on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to GPCR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.